See what’s trending right now
Stock Market Trendsin Financial Markets
4 hours ago

Insiders show mixed moves with Aehr Test Systems director selling stock, Loop Industries director buying shares, and Kirkov investing in Elite Pharmaceuticals, reflecting varied confidence in their companies.

Benchmark reiterates buy rating on Canaan stock with $2 price target

Investing.comFriday, June 20, 2025 at 11:54:39 AM
PositiveFinancial MarketsCryptocurrency/Investing
Benchmark reiterates buy rating on Canaan stock with $2 price target
Investment firm Benchmark is sticking with its optimistic outlook on Canaan, a major player in Bitcoin mining hardware. They’ve reaffirmed their "buy" rating and set a $2 price target for the stock, signaling confidence in its potential growth despite the volatile crypto market.
Editor’s Note: For anyone tracking crypto-related stocks, this is a vote of confidence in Canaan’s ability to weather the ups and downs of Bitcoin mining. Benchmark’s endorsement suggests they see long-term value here—whether that’s based on tech, market position, or future demand for mining rigs. If you’re into crypto investing, it’s worth keeping an eye on how this plays out.
— Curated via WP Now’s

Was this article worth reading? Share it

Latest from Financial Markets
Project Veritas Withdraws Lawsuit Against The New York Times
NeutralFinancial Markets
Conservative activist group Project Veritas has dropped its defamation lawsuit against The New York Times, ending a legal battle that began after the newspaper criticized the group's reporting methods. While neither side disclosed the reason for the withdrawal, it’s a quiet close to a high-profile clash over media ethics and free speech.
Editor’s Note: This might not be a bombshell resolution, but it’s a notable moment in the ongoing tension between activist journalism and mainstream media. Lawsuits like these often test the boundaries of press freedoms—so even a dropped case can hint at where those lines are drawn (or avoided altogether).
Kirkov buys $9639 in Elite Pharmaceuticals shares
PositiveFinancial Markets
Kirkov, likely an insider or executive at Elite Pharmaceuticals, just scooped up nearly $10,000 worth of the company's shares. This kind of move often signals confidence in the company's future—after all, why would someone invest their own money if they expected things to go south?
Editor’s Note: When company insiders buy up shares, it’s usually a quiet but telling vote of confidence. Investors keep an eye on these transactions because they hint at how leadership views the business’s prospects. If Kirkov is betting on Elite Pharmaceuticals, others might take a closer look too.
Salesforce CEO Benioff sells $600k in CRM stock
NeutralFinancial Markets
Salesforce CEO Marc Benioff has sold $600,000 worth of the company’s stock, according to recent filings. While insider sales can raise eyebrows, this is a relatively small portion of his overall holdings—more like pocketing some cash than a major divestment.
Editor’s Note: CEOs selling stock isn’t inherently alarming—they do it for all sorts of reasons, from personal expenses to diversification. But investors often watch these moves for hints about a leader’s confidence in the company. In this case, the amount is modest, so it’s unlikely to signal deeper concerns. Still, it’s a reminder that even top execs cash out sometimes.
Union Pacific nearing agreement to buy Norfolk Southern Bloomberg reports
NeutralFinancial Markets
Union Pacific, one of the biggest railroad operators in the U.S., is reportedly close to striking a deal to acquire its rival Norfolk Southern, according to Bloomberg. If finalized, this could reshape the freight rail industry by consolidating two major players—though regulators might have something to say about it.
Editor’s Note: Big railroad mergers don’t happen often, and this one could mean fewer choices for shippers and potentially higher costs down the line. But it might also streamline operations in an industry that’s been under pressure to improve efficiency. Keep an eye on whether regulators give it the green light—antitrust concerns could be a major hurdle.
Trump golfs in Scotland as Epstein questions persist
NegativeFinancial Markets
While Donald Trump enjoys a golf outing at his Scottish resort, the shadow of Jeffrey Epstein continues to loom. The timing raises eyebrows, as lingering questions about Trump’s past associations with the disgraced financier remain unanswered. It’s a classic Trump move—business as usual, even as controversies simmer in the background.
Editor’s Note: This isn’t just about a former president hitting the links—it’s about optics. Trump’s leisurely activities contrast sharply with unresolved scandals, reinforcing perceptions of indifference or evasion. For critics, it’s another example of his knack for deflecting scrutiny; for supporters, it might just be another day in the "witch hunt" narrative. Either way, it keeps the Epstein connection in the headlines, ensuring the story won’t fade quietly.

Why World Pulse Now?

Global Coverage

All major sources, one page

Emotional Lens

Feel the mood behind headlines

Trending Topics

Know what’s trending, globally

Read Less, Know More

Get summaries. Save time

Stay informed, save time
Learn more

Live Stats

Articles Processed

7,483

Trending Topics

112

Sources Monitored

191

Last Updated

4 hours ago

Live data processing
How it works

Mobile App

Available on iOS & Android

The mobile app adds more ways to stay informed — including offline reading, voice-enabled summaries, and personalized trend alerts.

Get it on Google PlayDownload on the App Store
Available now on iOS and Android

1-Minute Daily Briefing

Stay sharp in 60 seconds. Get concise summaries of today’s biggest stories — markets, tech, sports, and more

By subscribing, you agree to our Privacy Policy